Obesity pill data released by Viking Therapeutics Inc and AstraZeneca Plc at a big conference foreshadowed an increasingly ...

Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.

When Novo Nordisk reports earnings Wednesday morning, investors will be seeking reassurance that they haven’t overestimated ...

We recently compiled a list of the 8 Best European Stocks To Buy According to Hedge Funds. In this article, we are going to ...

AstraZeneca PLC shed GBP15 billion of market capitalization on Tuesday, after investors were underwhelmed by early data from a trial of a weight-loss pill. The company (UK:AZN) said its lead product ...

Zealand Pharma A/S said moderate doses of its experimental weight-loss drug helped patients pare pounds with less nausea than ...

The millennial-skewed telehealth platform Hims & Hers (HIMS) announced Monday that it will start offering customers a generic version of liraglutide, an older GLP-1 weight loss drug, next year. The ...

Novo Nordisk ( NVO, Financials) entered an exclusive agreement with Ascendis Pharma ( ASND, Financials) to license Ascendis's TransCon technology platform for developing novel treatments targeting ...

Armed with a bunch of Ozempic money, the Novo Nordisk Foundation — along with Denmark’s Export and Investment fund — is ...

Novo Nordisk is expected to report third-quarter earnings on Wednesday. Stock up 8.55% in a year, 7.45% year-to-date.

Catalent's revenue for fiscal first quarter ended Sept. 30 was $1.02 billion, marginally below analysts' estimates of $1.06 ...